Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 41 EP876 | DOI: 10.1530/endoabs.41.EP876

ECE2016 Eposter Presentations Pituitary - Clinical (83 abstracts)

ACRO-POLIS study: differences of symptoms and comorbidities in 472 acromegalic patients according the sex of patients and sources of clinical data

Philippe Caron 1 , Philippe Chanson 2 , Gérald Raverot 3 , Antoine Tabarin 4 , Anne Cailleux 5 , Brigitte Delemer 6 , Peggy Pierre Renoult 7 , Aude Houchard 8 , Pauline Cloitre 8 & Thierry Brue 9

1Department of Endocrinology, CHU Larrey, Toulouse, France; 2Department of Endocrinology, CHU Kremlin-Bicêtre, Kremlin-Bicêtre, France; 3Department of Endocrinology, Hôpital Neuro-Cardiologique, Lyon, France; 4Department of Endocrinology, CHU Haut Lévêque,
Bordeaux, France; 5Department of Endocrinology, CHU Bois Guillaume, Rouen, France; 6Department of Endocrinology, CHU Robert Debré, Reims, France; 7Department of Endocrinology, CHU Bretonneau, Tours, France; 8Ipsen Lab, Boulogne-Billancourt, France; 9Department of Endocrinology, CHU Conception, Marseille, France.

Introduction: Acromegaly is characterized by excessive secretion of GH and increased IGF-1 levels caused by benign pituitary adenoma. The ACRO-POLIS study describes symptoms and comorbidities of acromegaly at diagnosis in a large cohort of patients diagnosed between 2009 and 2014 in France.

Methodology: Observational, cross-sectional, multicentre study included adult patients with acromegaly diagnosed for less than 5 years. Data were collected retrospectively from patient medical files and from patients’questionnaires.

Results: 472 patients were included. Mean (±S.D.) age was 51.9 (±14.3) years and 57.2% were female. GH- and GH/PRL-secreting pituitary adenomas were reported in 78.8% and 18.2% of patients, respectively. Most patients had a macroadenoma (80.5%). At diagnosis, mean (±S.D.) GH level and IGF-1 level were 18.7 (±30.1) ng/L and 295 (±160) %ULN respectively. Mean time between symptom or comorbidity onset and diagnosis of acromegaly was 5.1 (±6.75) years. The symptoms are mainly morphological manifestations, snoring and weight gain and were detected earlier in females than in males [enlargement of hands: 7.4 (±7.4) years vs. 5.6 (±6.3) years; enlargement of feet: 6.7 (±6.7) years vs. 5.8 (±7.0) years; snoring: 9.1 (±8.5) years vs. 5.9 (±6.7) years; weight gain: 6.6 (±5.9) years vs. 4.9 (±5.7) years]. Majority of signs were predominantly reported in the patient’s questionnaires and less in the patient’s medical records. The rates of important symptoms reported only in questionnaires are: snoring (40.4%), weight gain (50.2%), loss of libido (74.4%), rachialgia (61.7%), asthenia (35.8%), arthropathy (30.4%).

Conclusion: In ACRO-POLIS study, symptoms and comorbidities associated with acromegaly were different in terms of time to diagnosis between males and females. Furthermore, the study highlights the value of collecting data directly from the patient’s questionnaire in complement with the patient’s medical record.

Article tools

My recent searches

No recent searches.